An international team of doctors led by Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer ...

India introduces Qartemi a groundbreaking CAR-T cell therapy to fight advanced blood cancers like B-cell Non-Hodgkin Lymphoma ...

An international team of doctors led by Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at The Tisch Cancer ...

Qartemi is a 'living drug' that has been approved by the Central Drugs Standard Control Organisation (CDSCO) for blood cancer ...

JW Therapeutics (HKEx: 2126), an independent and innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy ...

A "living drug" Qartemi has been approved for blood cancer patients in India who suffer from an advanced or relapsed stage of ...

[71] With the FDA approval of sipuleucel-T for prostate cancer in 2010, and promising data for Biovax-ID from Phase III trials in B-cell lymphoma ... dose 3F8/GM-CSF immunotherapy plus 13-cis ...

This has led researchers to explore CD24 as a target for immunotherapy ... In contrast, the role of CD24 in diffuse large B-cell lymphoma (DLBCL) appears to be less significant, indicating ...

Oct. 17, 2024 — Researchers discovered they could boost survival to 92% for patients with advanced Hodgkin lymphoma by adding the immunotherapy ... Aggressive B-Cell Lymphoma June 19, 2024 ...